Last checked at 18 Dec 2019 07:00
18 December 2019
Deltex Medical Group plc
("Deltex Medical" or the "Company")
Director Dealing
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), was informed yesterday that a number of Directors purchased ordinary shares in the Company ("Ordinary Shares") at a price of 1.12 pence per Ordinary Share and now hold the following number of Ordinary Shares as stated in the table below:
Director | Board position | Ordinary Shares purchased | Number of Ordinary Shares held post share purchase | Percentage of issued share capital held |
Nigel Keen | Non-Executive Chairman | 1,821,429 | 64,740,491 | 12.5% |
Julian Cazalet | Non-Executive Director | 892,857 | 9,397,927 | 1.8% |
David Moorhouse | Finance Director | 446,429 | 459,834 | 0.1% |
Sir Duncan Nichol | Non-Executive Director | 446,429 | 2,754,136 | 0.5% |
Mark Wippell | Non-Executive Director | 892,857 | 2,481,831 | 0.5% |
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 |
Nigel Keen, Chairman | investorinfo@deltexmedical.com |
Andy Mears, Chief Executive |
|
David Moorhouse, Group Finance Director |
|
|
|
Nominated Adviser & Broker |
|
Arden Partners plc | 020 7614 5900 |
Ciaran Walsh Dan Gee-Summons |
|
|
|
|
|
Joint Broker |
|
Turner Pope Investments (TPI) Ltd | 0203 657 0050 |
Andy Thacker Zoe Alexander | info@turnerpope.com |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in flow and measures such changes in 'real time'. Deltex Medical has been the only Group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for high risk surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA - and through distribution arrangements in approximately 40 other countries.
Note: This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them.
1
| Details of the persons discharging managerial responsibilities / person closely associated | |||||||||||||||||||
a)
| Names | A. Nigel Keen - Non Executive Chairman B. Julian Cazalet - Non Executive Director C. David Moorhouse - Finance Director D. Sir Duncan Nichol- Non Executive Director E. Mark Wippell - Non Executive Director
| ||||||||||||||||||
2
| Reason for the notification | |||||||||||||||||||
a)
| Position/status
| See 1(a) above for position - classified as a PDMR of Deltex Medical | ||||||||||||||||||
b)
| Initial notification /Amendment
| Initial | ||||||||||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a)
| Name
| Deltex Medical Group plc
| ||||||||||||||||||
b)
| LEI | 213800XN34P6LI8J6M39 | ||||||||||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||
a)
| Description of the financial instrument, type of instrument
| Ordinary shares of 1 penny each ("Ordinary Shares") | ||||||||||||||||||
b) | Identification code
| GB0059337583 | ||||||||||||||||||
c)
| Nature of the transaction
| Purchase of Ordinary Shares
| ||||||||||||||||||
d)
| Price(s) and volume(s) |
| ||||||||||||||||||
d)
| Aggregated information - Aggregated volume - Price | 4,500,0001.12 pence | ||||||||||||||||||
e)
| Date of the transaction | 17 December 2019 | ||||||||||||||||||
f)
| Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||||||||||||||||